Telitacicept Wins Dual China Approvals for IgA Nephropathy and Sjögren's Disease
VOR has more than doubled off its 52-week low of $3.626.
Summary
Vor Biopharma's collaborator, RemeGen, secured NMPA conditional approval for telitacicept in IgA nephropathy and full approval for Sjögren's disease in China. This follows an 8-K filed just minutes prior. The Sjögren's disease approval marks the first and only therapy for the condition in China. While RemeGen will commercialize in China, Vor Bio retains exclusive rights outside Greater China and is advancing its global Phase 3 programs for telitacicept. These approvals significantly validate the drug's efficacy and safety, de-risking Vor Bio's ongoing global development efforts and providing a strong positive signal for its potential in other markets.
At the time of this announcement, VOR was trading at $13.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $720.1M. The 52-week trading range was $3.63 to $65.80. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.